| Schedule of controlled substances; placement of fospropofol into schedule IV. Final rule. | |
| | |
MedLine Citation:
|
PMID: 19877370 Owner: HSR Status: MEDLINE |
Abstract/OtherAbstract:
|
With the issuance of this final rule, the Deputy Administrator of the Drug Enforcement Administration (DEA) places the substance fospropofol, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, into schedule IV of the Controlled Substances Act (CSA). As a result of this rule, the regulatory controls and criminal sanctions of schedule IV will be applicable to the manufacture, distribution, dispensing, importation, and exportation of fospropofol and products containing fospropofol. |
| | |
Authors:
|
|
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Federal register Volume: 74 ISSN: 0097-6326 ISO Abbreviation: Fed Regist Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-30 Completed Date: 2009-11-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7808722 Medline TA: Fed Regist Country: United States |
Other Details:
|
Languages: eng Pagination: 51234-6 Citation Subset: T |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anesthetics, Intravenous
/
classification Commerce / legislation & jurisprudence Drug and Narcotic Control / legislation & jurisprudence* Humans Hypnotics and Sedatives / classification Propofol / analogs & derivatives*, classification Substance-Related Disorders United States United States Food and Drug Administration |
| Chemical | |
Reg. No./Substance:
|
0/Anesthetics, Intravenous; 0/Hypnotics and Sedatives; 2078-54-8/Propofol; 258516-87-9/fospropofol disodium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Revised medical criteria for evaluating malignant neoplastic diseases. Final rule.
Next Document: Direct metallation of thienopyrimidines using a mixed lithium-cadmium base and antitumor activity of...